Cybin Corp.: A Diversified Play on Psychedelic Therapeutics
Ryan Allway
August 26th, 2020
Exclusive, Psychedelics, Top Story
More than 700 million people around the world suffer from a mental illness, addiction or eating disorder, according to the World Health Organization, which costs the global economy $2.5 trillion each year in direct and indirect costs. Despite these significant costs, large pharmaceutical companies have stopped searching for the next Prozac.
Psychedelics, including psilocybin, MDMA and other substances, have emerged as potential therapeutics for mental illnesses following decades of prohibition. Johns Hopkins launched a psychedelics research unit, MAPS raised $30 million for a Phase III clinical trial and the FDA granted ‘breakthrough therapy’ status to several psilocybin treatments.
Cybin Corp. aims to build upon these early successes by manufacturing its own proprietary API, conducting clinical trials targeting major depressive disorder and smoking addiction while developing innovative delivery mechanisms like its oral thin film and microdosing technology.
Click here to learn more about becoming an early stage investor and receive corporate updates.
Developing a Proprietary API
A key bottleneck in conducting clinical trials in psychedelics is securing psilocybin. It takes academics about a year to secure a supply for their studies since they require institutional review board approval, FDA approval and DEA approval. These delays are both costly and jeopardize the inroads that psychedelics have made in providing treatment options.
In the near-term, Cybin Corp. secured a GMP source for psilocybin for its oral thin film manufacturing and its initial clinical trial targeting moderate depressive disorder. The source can ship the substance to any academic or research facility with a drug establishment license and any other necessary approvals in place.
The company also signed an agreement with Smart Medicines GMP Inc. to manufacture psilocybin for future clinical trials. The goal is to expand production into other analogues found within magic mushrooms and scale production to meet the needs of academic and corporate institutions in need of a source of synthetic psychedelic substances.
Conducting Clinical Trials
Cybin Corp. plans to conduct a series of clinical trials designed to bring approved therapeutics to market. In choosing indications, the company’s management team has focused on large markets where early research has shown tremendous promise. The goal is to become the first approved product and capture maximum market share.
The company plans to conduct a Phase 2a and Phase 2b clinical trials in patients with major depressive disorder in partnership with the University of West Indies. By following strict ICH and GCP guidelines, the study will allow the use of data collected to enter other jurisdictions, including the United States, Canada and Europe.
In addition, the company is planning a Phase 2 clinical trial in patients with smoking addiction. Early research has shown that psilocybin could decrease smoking by 80% within six months, which exceeds rates for other behavioral or pharmacological therapies. The clinical trial will be conducted in the United States and Canada.
Click here to learn more about becoming an early stage investor and receive corporate updates.
Developing Delivery Mechanisms
Cybin Corp. has developed two delivery mechanisms that could transform psychedelic therapies by reducing the side effects of psilocybin and making it easier to deliver the benefits. By developing these in conjunction with running clinical trials, the company is taking a holistic approach to the market that could provide a competitive edge over the coming years.
The company’s oral thin film technology is designed to increase bioavailability and flexibility at a significantly lower cost than pill-based therapeutics. Patients can administer the therapy without water at any time during the day while direct access to the carotid artery provides a more effective delivery than going through the stomach and liver.
In addition to oral thin film, the company is testing microdosing technology that would provide roughly one-tenth of the ‘trip’ dose of a psychedelic drug to avoid triggering hallucinations but still provide cognitive benefits. Management is working with the Canadian Centre for Psychedelic Sciences to determine the safety and efficacy of microdosing techniques.
Looking Ahead
Cybin Corp. is one of the most diversified and expansive companies in the nascent psychedelics industry. With a focus on everything from API procurement to delivery mechanisms, the company provides exposure to nearly every corner of the therapeutic market. The company is also working on over-the-counter therapeutics using functional mushroom ingredients.
With plans to list on the Canadian Securities Exchange (CSE), investors may want to follow the company’s efforts over the coming months. Accredited investors interested in participating in earlier rounds of financing may also have opportunities ahead.
Sign up to download the company’s investor presentation and receive corporate updates today!
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
CB Therapeutics, Inc. is a biotechnology company focusing on the innovative production of high value molecules, compounds and rare ingredients from simple feedstock utilizing many different types of hosts and systems, including yeast, bacteria and cell-free expression systems.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
